Persistent disparities in access to guideline‑directed medical therapy (GDMT) for heart failure (HF) remain a major driver of avoidable morbidity and mortality in underserved populations. Advanced practice providers (APPs), including nurse practitioners (NPs) and PAs, are uniquely positioned to close these gaps through structured, protocol‑driven optimization of the "four pillars" of GDMT (ARNI/ACEI/ARB, evidence‑based beta‑blocker, mineralocorticoid receptor agonist [MRA], and SGLT2 inhibitor), coupled with targeted interventions on social drivers of health (SDOH) such as medication affordability, transportation, health literacy and social support. This article synthesizes recent evidence on HF inequities and operationalizes an APP‑led model with pragmatic tactics, metrics and implementation pearls for real‑world practice.¹

Disparities in GDMT Uptake

Despite compelling survival and hospitalization benefits from comprehensive GDMT across the HF spectrum, real‑world implementation remains suboptimal and unevenly distributed. Registry and guideline analyses show that less than one in five eligible patients leave the hospital on all four drug classes, and uptake varies by insurance status and documented social needs, gaps that disproportionately affect patients served by safety‑net systems.²

Multiple reviews document racial/ethnic and socioeconomic inequities across prevention, diagnosis, pharmacotherapy and advanced therapies. Contributors include access barriers, financial toxicity, clinical inertia, structural racism and underrepresentation in trials.³

Why APPs?

Evidence from nurse‑ and pharmacist‑led programs shows higher rates of GDMT initiation, faster uptitration and signals for reduced HF hospitalizations vs. usual care. Dedicated GDMT clinics and hybrid telehealth models, often staffed and coordinated by APPs, have demonstrated large absolute gains in quadruple therapy and reduced readmissions.⁴

A Practical APP‑Led Equity Framework

An APP‑driven, team‑based model that integrates equity‑first workflows into day‑to‑day GDMT optimization could help address these challenges and optimize treatment. The framework aligns to four SDOH domains: medication access, transportation, health literacy and social support, with specific actions, metrics and sample documentation.

Medication Access and Affordability

Equity Problem

High out‑of‑pocket (OOP) costs and formulary barriers impede adoption of ARNIs and SGLT2 inhibitors, especially for patients with Medicare/Medicaid or no insurance. Prior authorization delays further exacerbate underuse.⁵

What the Evidence Shows

Investigators estimate typical retail prices >$500-$700/month for SGLT2 inhibitors and sacubitril/valsartan, with OOP burdens that disproportionately affect low‑income and minority patients and contribute to physician inertia.⁶

APP Strategies

• Standardized Coverage Pathways: Build electronic health record (EHR) order sets that auto‑trigger preferred formulary options, prior authorization templates and manufacturer assistance links. Embed social work/pharmacy referral at point‑of‑care.⁷
• Start Now, Optimize Later Philosophy: Initiate all four pillars at low dose during the first APP visit whenever clinically safe (blood pressure [BP], potassium, estimated glomerular filtration rate [eGFR] permitting), then titrate via rapid follow‑ups. This approach counters therapeutic inertia and has been successful in APP‑led GDMT clinics.⁶
• Leverage Pharmacist Partners: Co‑manage prior authorization, dose adjustments and side‑effect mitigation. Integration of pharmacists in safety‑net HF clinics improved RAAS‑pathway optimization and shortened time to goal.
• Track an Equity‑Sensitive GDMT Score: Use a simple composite (use and dose of ARNI/ACEI/ARB, beta‑blocker, MRA, SGLT2 inhibitor) with dashboards stratified by insurance, language and ZIP code to surface inequities and guide outreach.⁷

Metrics to Monitor

Time from referral to first fill; percent of patients on quadruple therapy at four and 12 weeks; percent of patients at ≥50% target doses; discontinuation rates by payer.⁷

Transportation Barriers

Equity Problem

Missed appointments due to lack of transportation undermine timely titration. While a single pragmatic trial of generic ridesharing offers showed no reduction in no‑shows, broader evidence across multiple modalities indicates that nonemergency medical transportation (NEMT) interventions can reduce missed visits.⁸

APP Strategies

• Screen Everyone: Add a one‑click transportation screener to the vitals section ("Any difficulty getting to visits or pharmacy this month?") that triggers same‑day NEMT scheduling or telehealth conversion.⁸
• Use Targeted, Not Blanket, Rides: Prioritize rides for high‑risk GDMT titration windows (first four to eight weeks) and for lab monitoring visits (basic metabolic panel, potassium), consistent with evidence that generic rides may not move the needle without targeted delivery.⁵
• Tele‑Titration With Home Monitoring: Alternate in‑person and video visits. Pair with home BP/weight monitoring to enable safe medication uptitration and earlier detection of intolerance, approaches associated with lower mortality and HF rehospitalization in meta‑analyses.⁹

Metrics to Monitor

No‑show rate during titration phase; time between GDMT dose escalations; percent of visits completed via telehealth among patients screening positive for transport barriers.⁹

Health Literacy

Equity Problem

Inadequate health literacy is associated with higher mortality and readmissions in HF. Patients with limited literacy struggle with complex regimens and sodium/diuretic self‑management.¹

APP Strategies

• Assess, Don't Assume: Incorporate a validated single‑item screener ("How confident are you filling out medical forms by yourself?") or brief tools. Document literacy level to tailor teaching. Evidence links low literacy to worse outcomes; identifying it is actionable.
• Teach‑Back + Micro‑Tools: Use teach‑back on each medication change. Provide a one‑page medication list with icons (morning/evening, with/without food) and a "when to call" action plan. Such approaches are associated with improved self‑care and reduced readmissions in HF education programs.¹
• Activation Nudges: Send a two-to-three-minute pre‑visit video and checklist emphasizing GDMT goals. Patient‑activation tools have increased medication initiation/intensification vs. usual care.^1,4,10

Metrics to Monitor

Percent of patients with literacy screening documented; teach‑back documentation rate; 30‑day post discharge follow‑up completion, associated with lower readmissions in HF.^1,11

Social Support and Caregiver Engagement

Equity Problem

Many underserved patients rely on informal caregivers who themselves experience burden, affecting the patient's symptoms, quality of life and self‑care. Deliberate caregiver engagement can improve adherence and clinical stability.^1,4

APP Strategies

• Identify the Dyad: Document a primary caregiver/support person and obtain consent to share care plans. Caregiver contribution to self‑care mediates improved patient quality of life in HF.
• Structure Visits Around the Dyad: Invite caregivers to APP titration visits (virtual or in‑person) and provide a concise "GDMT roadmap" that lists target doses, lab checks and red‑flag symptoms. Systematic reviews support caregiver‑centered, active engagement and education ("CARE" framework).¹²
• Screen For Caregiver Strain: Use a brief tool at baseline and when regimens intensify. Higher caregiver strain correlates with worse patient symptoms and lower patient quality of life.¹⁰

Metrics to Monitor

Caregiver identified in chart; caregiver attendance at visits; changes in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores during titration in APP clinics.⁶

Building the APP‑Led Model: Operations and Workflow

Referral Triggers: Any HF patient not on quadruple therapy or not at ≥50% target doses is auto‑referred to the APP GDMT clinic upon discharge or after any HF clinic visit. Equity flags (Medicaid/uninsured, language need, high SDOH risk) prompt expedited scheduling.¹²

1. Rapid‑Cycle Titration: Weekly/bi‑weekly APP touchpoints (alternating phone/video and in‑person for labs) to reach maximally tolerated doses in approximately 12 weeks, mirroring timeframes achieved in dedicated GDMT programs.⁶
2. Standing Protocols: APP‑signed algorithms specifying hemodynamic and laboratory thresholds for initiation/increase, with pharmacist cosign for drug-drug interactions. Meta‑analyses show nurse/pharmacist‑led titration improves initiation and dose achievement.⁶
3. Data and Feedback: EHR dashboards display GDMT score and titration velocity by clinic, race/ethnicity, payer, preferred language and neighborhood deprivation. Monthly feedback to teams has improved prescribing rates in health system implementations.⁷
4. Tele‑Equity Stack: Standard issue home BP cuff and digital scale and daily weight/BP uploads when feasible. Telemonitoring programs are associated with reductions in mortality and HF readmissions when monitoring is at least daily and includes BP.¹⁰

Measuring Impact on Outcomes

Observational and controlled studies of APP‑centered, team‑based medication optimization demonstrate:

• Greater GDMT use (e.g., quadruple therapy 49% vs. 4% with usual care; large increases in ARNI/MRA/SGLT2i use) and fewer HF hospitalizations at three months.³
• Marked improvements in optimal GDMT (e.g., from 12% to 91% within approximately 13 weeks) with clinically meaningful gains in KCCQ and six‑minute walk distance.⁶
• Evidence that nurse/pharmacist‑led titration doubles the likelihood of initiating and uptitrating key classes vs. usual care.⁶

When programs explicitly address SDOH, reducing OOP burden, solving for transportation barriers, improving literacy and engaging caregivers, they target the very mechanisms that create GDMT inequities identified in contemporary registry analyses.⁵

Policy and Health‑System Levers

• Coverage Advocacy: Hospital and system leadership should pursue value‑based pharmacy contracts and streamlined prior authorization for ARNIs/SGLT2i, given documented plan‑level restrictions and cost‑sharing barriers.⁵
• Equity‑Embedded Quality Metrics: Incorporate GDMT score and titration velocity into service line dashboards, stratified by equity variables. HF societies and large centers have demonstrated EHR‑based approaches to track and improve performance.⁷
• Resource Allocation to APP Clinics: Funding APP‑pharmacist dyads in safety‑net settings is supported by studies showing improved GDMT and fewer hospitalizations, leading to cost-savings in readmission penalties.⁴

Moving Foward

Equitable HF care demands more than knowledge of guidelines, it requires operational excellence in implementing GDMT for every patient, regardless of insurance, literacy or ZIP code. APPs are ideally situated to lead this transformation. By uniting protocolized titration with SDOH‑focused interventions, lowering medication costs, assuring transportation, tailoring education and engaging caregivers, APP‑led models can close GDMT gaps and improve survival, quality of life and hospitalization outcomes for underserved populations.¹²

This article was authored by Luis E. Farfan, DNP, AGACNP-BC, CCRN, FHFSA, an NP in the Cardiac Care Unit at New York Presbyterian Hospital - Columbia University in New York, and adjunct professor at Mercy University, School of Nursing.

References

1. Deek H, Itani L, Davidson PM. Literacy critical to heart failure management: a scoping review. Heart Failure Reviews.2021;26(6):1413-1419. 10.1007/s10741-020-09964-6.
2. High Cost of Heart failure Treatment: Stories From the Frontline. Cardiology Magazine. October 2024. Available here.
3. Coons JC, Kliner J, Mathier MA, et al. Impact of a medication optimization clinic on heart failure hospitalizations. Am J Cardiol. 2023;188:102-109. 10.1016/j.amjcard.2022.11.025.
4. Shah SP, Dixit NM, Mendoza K., et al. Integration of clinical pharmacists into a heart failure clinic within a safety-net hospital. J Am Pharmacists Assoc. 2022;62(2):575-579.e2. 10.1016/j.japh.2021.11.012.
5. Chaiyachati KH, Hubbard RA, Yeager A, et al. (2018). Association of rideshare-based transportation services and missed primary care appointments: a clinical trial. JAMA Intern Med. 2018;178(3): 383-389. 10.1001/jamainternmed.2017.8336.
6. Cohen LP, Paquette C, Vassilopoulos M, et al. Expanded results from a dedicated guideline-directed medical therapy clinic. J Cardiac Fail.2025;10.1016/j.cardfail.2025.09.019.
7. Harnessing tech for GDMT optimization and readmission reduction (Conference slide deck). (2025). Cleveland Clinic HVTI. Available here.
8. Shekelle PG, Begashaw MM, Miake-Lye IM, et al. (2022). Effect of interventions for non-emergent medical transportation: a systematic review and meta-analysis. BMC Public Health. 2022;22(1): 799-812. 10.1186/s12889-022-13149-1.
9. Masotta V, Dante A, Caponnetto V, et al. Telehealth care and remote monitoring strategies in heart failure patients: A systematic review and meta-analysis. Heart Lung. 2024;64:149-167. 10.1016/j.hrtlng.2024.01.003.
10. De Lathauwer ILJ, Nieuwenhuys WW, Hafkamp F, et al. Remote patient monitoring in heart failure: A comprehensive meta‐analysis of effective programme components for hospitalization and mortality reduction. Eur J Heart Fail. 2025;27(9):1670-1685. 10.1002/ejhf.3568.
11. Bilicki DJ, Reeves MJ. Outpatient follow-up visits to reduce 30-day all-cause readmissions for heart failure, COPD, myocardial infarction, and stroke: a systematic review and meta-analysis. Preventing Chronic Disease. 2024;21: E74. DOI: 10.5888/pcd21.240138.
12. Aggarwal R, Vaduganathan M, Chiu N, Bhatt DL. Out-of-pocket costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. Circulation Heart Failure. 2022;15(3), e009099. 10.1161/CIRCHEARTFAILURE.121.009099.

Clinical Topics: Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Acute Heart Failure

Keywords: Cardiology Magazine, ACC Publications, CM-May-2026, Health Equity, Heart Failure, Patient Care Team, Global Burden of Disease, Care Team